Skip to NavigationSkip to content

Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure

Published on 26/04/19 at 10:00am

Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from the market as a treatment for advanced soft tissue sarcoma (STS) due to the drug’s failure to adequately address the condition in Phase 3 trials.

Lartruvo failed to meet its primary endpoint of improvement in overall survival in the ANNOUNCE trial earlier this year.

In order to make sure that patients already using the drug do not lose access once it is no longer available on the market, Lilly has announced it is working to launch a programme to minimise interruption to their ongoing treatment, provided they do so in consultation with a physician and have been made aware of the risks of the medicine.

However, no new patients will be able to begin treatment with the drug in this indication once it has been withdrawn outside of ongoing clinical trials.

"Lilly wants to ensure that patients and physicians feel supported during this important time," said Anne White, President at Lilly Oncology. "Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer. Establishing this programme will give patients who are currently taking Lartruvo the opportunity to continue their treatment programme uninterrupted."

Matt Fellows


Found full of informative blog on Eli Lilly which has revealed it is to withdraw its platelet-derived growth factor receptor alpha blocking antibody Lartruvo.


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches